Download PDF

下载PDF

Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disorders

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced seven presentations on AXS-12 and solriamfetol at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society, being held September 24-27, 2024, in Seville, Spain.

2024年9月24日，纽约（环球通讯社）--Axsome Therapeutics，Inc.（纳斯达克：AXSM），一家开发和提供中枢神经系统（CNS）疾病治疗新疗法的生物制药公司，今天宣布在2024年9月24日至27日在西班牙塞维利亚举行的欧洲睡眠研究学会第27届大会“睡眠欧洲2024”上就AXS-12和solriamfetol进行了七次演讲。

Featured presentations include data from the SYMPHONY Phase 3 trial of AXS-12 in narcolepsy, findings from the CRESCENDO patient survey underscoring the unmet needs of patients with type 1 narcolepsy, and previously reported data on solriamfetol demonstrating improvement in cognitive function in patients with excessive daytime sleepiness (EDS) associated with OSA and narcolepsy..

特色介绍包括来自AXS-12发作性睡病SYMPHONY 3期试验的数据，CRESCENDO患者调查的结果强调了1型发作性睡病患者未满足的需求，以及先前报道的关于solriamfetol的数据显示，与OSA和发作性睡病相关的白天过度嗜睡（EDS）患者的认知功能有所改善。。

Details for the presentations are as follows:

演示的详细信息如下：

AXS-12:

AXS-12：

Title: AXS-12 for the Treatment of Narcolepsy: Topline Results from the Phase 3 SYMPHONY TrialPoster Presentation Date and Time: Wednesday, September 25, 12:15 - 1:15 p.m. and 4:00 - 5:45 p.m. CESTLead Author: Michael Thorpy, MD, Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and Professor of Neurology at Albert Einstein College of Medicine, New York, NY, USAPoster Number: P254.

标题：用于治疗嗜睡症的AXS-12：第三阶段SYMPHONY TrialPoster的Topline结果介绍日期和时间：9月25日星期三，下午12:15-1:15和下午4:00-5:45。CESTLead作者：Michael Thorpy，医学博士，Montefiore医学中心睡眠-觉醒障碍中心主任，美国纽约州阿尔伯特·爱因斯坦医学院神经病学教授海报编号：P254。

Title: CRESCENDO: Results from a Survey of Symptom Burden and Quality of Life in Patients with Narcolepsy Type 1Poster Presentation Date and Time: Wednesday, September 25, 12:15 - 1:15 p.m. and 4:00 - 5:45 p.m. CESTLead Author: Michael Thorpy, MD, Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and Professor of Neurology at Albert Einstein College of Medicine, New York, NY, USAPoster Number: P265.

。

Solriamfetol:

索拉唑：

Title: Solriamfetol and Maintenance of Wakefulness Outcomes in Patients with Narcolepsy and Obstructive Sleep ApneaOral Presentation Date and Time: Tuesday, September 24, 9:55 - 10:01 a.m. CEST Poster Presentation Date and Time: Wednesday, September 25, 12:15 - 1:15 p.m. and 4:00 - 5:45 p.m. CESTLead Author: Michael Thorpy, MD, Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and Professor of Neurology at Albert Einstein College of Medicine, New York, NY, USAPoster Number: P475.

标题：发作性睡病和阻塞性睡眠呼吸暂停患者的Solriamfetol和清醒结果的维持介绍日期和时间：9月24日星期二上午9:55-10:01 CEST海报介绍日期和时间：9月25日星期三下午12:15-1:15和下午4:00-5:45 CESTLead作者：医学博士迈克尔·索普，蒙特菲奥医学中心睡眠-觉醒障碍中心主任，美国纽约州阿尔伯特·爱因斯坦医学院神经病学教授海报编号：P475。

Title: Effects of Solriamfetol on Cognition in Patients with Excessive Daytime Sleepiness Associated with NarcolepsyPoster Presentation Date and Time: Wednesday, September 25, 12:15 - 1:15 p.m. and 4:00 - 5:45 p.m. CESTLead Author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology, Johannes Gutenberg-University, Mainz, GermanyPoster Number: P197.

标题：Solriamfetol对与发作性睡病相关的白天过度嗜睡患者认知的影响呈现日期和时间：9月25日星期三，下午12:15-1:15和下午4:00-5:45。CESTLead作者：Yaroslav Winter，医学博士，美因茨综合癫痫和睡眠医学中心，德国美因茨约翰内斯古腾堡大学神经病学系海报编号：P197。

Title: Real-world Use of Solriamfetol for Excessive Daytime Sleepiness in Patients Reporting Anxiety or DepressionPoster Presentation Date and Time: Friday, September 27, 10:45 a.m. - 1:30 p.m. CESTLead Author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology, Johannes Gutenberg-University, Mainz, Germany Poster Number: P198.

标题：报告焦虑或抑郁的患者白天过度嗜睡时使用Solriamfetol的现实世界海报展示日期和时间：9月27日星期五上午10:45至下午1:30。CESTLead作者：Yaroslav Winter，医学博士，美因茨综合癫痫和睡眠医学中心，德国美因茨约翰内斯古腾堡大学神经病学系海报编号：P198。

Title: SURWEY: Treatment of Excessive Daytime Sleepiness with Solriamfetol: Initiation, Titration, and OutcomePoster Presentation Date and Time: Thursday, September 26, 12:00 - 1:30 p.m. and 5:30 – 6:45 p.m. CESTLead Author: Samantha Floam, DMD, Axsome TherapeuticsPoster Number: P799

标题：SURWEY：用Solriamfetol治疗白天过度嗜睡：开始，滴定和结果海报展示日期和时间：9月26日星期四，下午12:00-1:30和下午5:30-6:45。CESTLead作者：Samantha Floam，DMD，Axsome Therapeutics主题号：P799

Title: Effects of Solriamfetol on Cognition in Obstructive Sleep Apnea with Excessive Daytime Sleepiness and Impaired CognitionPoster Presentation Date and Time: Friday, September 27, 10:45 a.m. - 1:30 p.m. CESTLead Author: Hans Van Dongen, PhD, Professor at Washington State University Poster Number: P1248.

标题：Solriamfetol对白天嗜睡过度和认知障碍的阻塞性睡眠呼吸暂停患者认知的影响海报展示日期和时间：9月27日星期五上午10:45至下午1:30。CESTLead作者：Hans Van Dongen博士，华盛顿州立大学教授海报编号：P1248。

About Axsome Therapeutics

关于Axsome Therapeutics

Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions.

Axsome Therapeutics，Inc.是一家生物制药公司，开发并提供针对治疗选择有限的中枢神经系统（CNS）疾病的新型疗法。通过开发具有新作用机制的治疗选择，我们正在改变治疗中枢神经系统疾病的方法。

At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company’s website at www.axsome.com..

。有关更多信息，请访问公司网站www.axsome.com。。

Forward Looking Statements

前瞻性声明

Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.

本新闻稿中讨论的某些事项是“前瞻性声明”。在某些情况下，公司可能会使用“预测”，“相信”，“潜在”，“继续”，“估计”，“预期”，“预期”，“计划”，“打算”，“可能”，“可能”，“可能”，“可能”，“将会”，“应该”或其他表达未来事件或结果不确定性的词语来识别这些前瞻性陈述。

In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the continued commercial success of the Company’s Sunosi® and Auvelity® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the t.

特别是，公司关于趋势和潜在未来结果的声明就是此类前瞻性声明的例子。前瞻性陈述包括风险和不确定性，包括但不限于公司Sunosi®和Auvelity®产品的持续商业成功，以及公司努力获得与solriamfetol和/或AXS-05有关的任何其他指示的成功；公司维持和扩大付款人覆盖范围的能力；公司正在进行的临床试验和公司当前候选产品的预期临床试验的成功率、时间和成本，包括关于开始时间、注册速度和完成试验的声明（包括公司完全资助公司披露的临床试验的能力，假设公司目前预计的收入或费用没有实质性变化），无效分析和中期结果的接收，这些不一定表明公司正在进行的临床试验的最终结果，和/或数据读数，以及支持公司当前候选产品提交新药申请（“NDA”）所需的研究数量或类型或结果的性质；公司有能力资助额外的临床试验，以继续推进公司的候选产品；t。

Investors:Mark JacobsonChief Operating Officer(212) 332-3243mjacobson@axsome.com

投资者：马克·雅各布森首席运营官（212）332-3243mjacobson@axsome.com

Media:Darren OplandDirector, Corporate Communications(929) 837-1065dopland@axsome.com

媒体：Darren Opland公司传播总监（929）837-1065dopland@axsome.com

Source: Axsome Therapeutics, Inc.

来源：Axsome Therapeutics，Inc。